Method of detecting human matrix metalloproteinase 9 using antibodies

Abstract

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

1 - 54 . (canceled) 
     
     
         55 . A method of detecting human MMP9 in a sample, comprising:
 a) contacting the sample with an antibody or fragment thereof wherein the antibody or fragment thereof comprising a light chain variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ. ID NO: 42, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 43, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 44; and,   b) detecting binding of the antibody or fragment thereof to human MMP9 in the sample, thereby detecting the presence of the human MMP9.   
     
     
         56 . The method of  claim 55 , further comprising the step of comparing the amount of binding detected in the sample to an amount of binding to a control sample. 
     
     
         57 . The method of  claim 55 , wherein the sample is a tissue or fluid sample from a subject. 
     
     
         58 . The method of  claim 57 , wherein the fluid sample is a blood, plasma, serum, whale blood, saliva, urine, or semen sample. 
     
     
         59 . The method of  claim 57 , therein the tissue sample is a formalin-fixed sample or a frozen sample. 
     
     
         60 . The method of  claim 55 , wherein the antibody or fragment thereof is labeled with a detectable moiety. 
     
     
         61 - 65 . (canceled) 
     
     
         66 . The method of  claim 60 , wherein the label moiety radioisotope, a fluorescent or chemiluminescent compound, or an enzyme. 
     
     
         67 . The method of  claim 55 , wherein the presence or absence of the human MMP9 indicate the presence, absence, or severity of an MMP9-associated disease or condition. 
     
     
         68 . The method of  claim 67 , wherein the disease or condition is cancer, autoimmune or inflammatory disease. 
     
     
         69 . A method of detecting MMP9 in a sample, comprising:
 a) contacting the sample with an antibody or fragment thereof having a light chain variable domain comprising the amine acid sequence set forth in SEQ ID NO: 41; and,   b) detecting binding of the antibody or fragment thereof to MMP9 in the sample, thereby detecting the presence of the human MMP9.   
     
     
         70 . The method of  claim 69 , further comprising the step of comparing the amount of binding detected in the sample to an amount of binding to a control sample. 
     
     
         71 . The method of  claim 69 , wherein the sample is a tissue or fluid sample from a subject. 
     
     
         72 . The method of  claim 71 , wherein the fluid sample blood, plasma, serum, whole blood, saliva, urine, or semen sample. 
     
     
         73 . The method of  claim 71 , wherein the tissue sample is a formalin-fixed sample or a frozen sample. 
     
     
         74 . The method of  claim 69 , wherein the antibody or fragment thereof is labeled with a detectable moiety. 
     
     
         75 . The method of  claim 74 , wherein the label moiety is radioisotope, a fluorescent or chemiluminescent compound, or an enzyme. 
     
     
         76 . The method wherein the presence or absence of MMP9 indicate the presence, absence, or severity of an MMP9-associated disease or condition. 
     
     
         77 . The method of  claim 76 , wherein the disease or condition is cancer, autoimmune or inflammatory disease. 
     
     
         78 . A method of inhibiting MMP9 in a sample, comprising contacting the sample with an antibody or fragment thereof, wherein the antibody or fragment thereof comprising a light chain variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 42, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 43, and a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 44. 
     
     
         79 . The method of  claim 70 , wherein the light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 41.